BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BIOCRYST PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$8.07+0.28 (+3.59%)

Close on Oct 19, 2026

Market cap: $2.14B
P/E (TTM): –
Dividend yield: –

BIOCRYST PHARMACEUTICALS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	875	451	331	271	157	18	49	21	25	26	48	14	17	26	20	62	75
Cost of Revenue	19	12	4.48	6.41	7.23	1.55	3.73	–	1.14	2.30	1.37	0.00	–	–	–	0.09	4.54
Gross Profit	856	438	327	264	150	16	45	–	24	24	47	14	–	–	–	62	70
Research & Development	166	175	217	253	209	123	107	85	67	61	73	52	42	49	57	84	74
Selling, General & Admin	349	266	214	159	119	68	37	30	14	11	13	7.46	6.01	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	7.46	6.01	9.13	12	12	10
Advertising Expenses	14	14	14	15	5.71	6.57	0	0	0	0	0.10	0.29	–	–	–	–	–
Total Costs & Expenses	534	453	435	419	335	193	148	115	83	75	88	59	48	60	69	97	88
Operating Income	341	-2.54	-104	-148	-178	-175	-99	-94	-57	-49	-39	-46	-31	-34	-50	-34	-14
Interest Expense	79	99	108	99	59	15	12	9.18	8.57	6.49	5.20	5.00	4.78	4.67	3.77	–	–
Other Non-Operating Income	-74	-84	-123	-96	–	–	–	–	–	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	6.31	1.26	–	–	–	–	–	–	–	–	–	–	-0.10	1.76	–	1.03	–
Gain (Loss) on Sale of Assets	3.57	0	0	–	–	–	–	-0.01	0.01	-0.02	–	-0.03	0.05	–	–	–	–
Pretax Income	267	-87	-226	-244	-182	-183	-109	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	3.53	1.93	0.31	2.73	2.25	0	0	0	0	0	0	17	8.57	7.00	–	–	–
Net Income	264	-89	-227	-247	-184	-183	-109	-101	-66	-55	-43	-45	-30	-39	-57	-34	-13
EPS (Basic)(per share)	1.26	-0.43	-1.18	-1.33	-1.03	-1.09	-940.00	-0.98	-0.78	-0.75	-0.59	-0.68	-0.55	-0.79	-1.26	-0.76	-0.35
EPS (Diluted)(per share)	1.21	-0.43	-1.18	-1.33	-1.03	-1.09	-940.00	-0.98	-0.78	-0.75	-0.59	-0.68	-0.55	-0.79	-1.26	-0.76	-0.35
Shares Outstanding (Basic, Weighted)(shares)	210	207	192	186	179	167	–	–	–	–	–	67	55	49	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	219	207	192	186	179	167	116	103	84	74	73	67	55	49	–	–	–
EBITDA	342	-1.30	-102	-147	-177	-174	-99	-93	-57	-48	-39	-46	-30	-33	-49	-32	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 97.8%
Operating margin: -33.3%
Net margin: -40.9%
Return on equity, FY2025: -88.7%

Financial strength

Current ratio: 2.32
Debt to equity: -0.87
Debt to assets: 70.9%
Cash to current liabilities: 74.2%

Valuation

P/E ratio: –
Price to sales: 2.27
Price to book: –
Dividend yield: –